These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 26116553)

  • 41. Thiopurines are associated with a reduction in surgical re-resections in patients with Crohn's disease: a long-term follow-up study in a regional and academic cohort.
    van Loo ES; Vosseberg NW; van der Heide F; Pierie JP; van der Linde K; Ploeg RJ; Dijkstra G; Nieuwenhuijs VB
    Inflamm Bowel Dis; 2013 Dec; 19(13):2801-8. PubMed ID: 24189041
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of infliximab therapy after early endoscopic recurrence following ileocolonic resection of Crohn's disease: a prospective pilot study.
    Yamamoto T; Umegae S; Matsumoto K
    Inflamm Bowel Dis; 2009 Oct; 15(10):1460-6. PubMed ID: 19266566
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Strategies for the prevention of postoperative recurrence of Crohn's disease.
    Yamamoto T; Watanabe T
    Colorectal Dis; 2013 Dec; 15(12):1471-80. PubMed ID: 23809911
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Postoperative therapy with infliximab for Crohn's disease: a 2-year prospective randomized multicenter study in Japan.
    Fukushima K; Sugita A; Futami K; Takahashi KI; Motoya S; Kimura H; Yoshikawa S; Kinouchi Y; Iijima H; Endo K; Hibi T; Watanabe M; Sasaki I; Suzuki Y;
    Surg Today; 2018 Jun; 48(6):584-590. PubMed ID: 29383596
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Genetic polymorphisms predict response to anti-tumor necrosis factor treatment in Crohn's disease.
    Netz U; Carter JV; Eichenberger MR; Dryden GW; Pan J; Rai SN; Galandiuk S
    World J Gastroenterol; 2017 Jul; 23(27):4958-4967. PubMed ID: 28785150
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Management of post-operative Crohn's disease in 2017: where do we go from here?
    Nguyen V; Kanth R; Gazo J; Sorrentino D
    Expert Rev Gastroenterol Hepatol; 2016 Nov; 10(11):1257-1269. PubMed ID: 27678049
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti-Tumor Necrosis Factor Therapy for Crohn's Disease: A Meta-analysis of Placebo-controlled Trials.
    Jones JL; Kaplan GG; Peyrin-Biroulet L; Baidoo L; Devlin S; Melmed GY; Tanyingoh D; Raffals L; Irving P; Kozuch P; Sparrow M; Velayos F; Bressler B; Cheifetz A; Colombel JF; Siegel CA
    Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2233-40.e1-2; quiz e177-8. PubMed ID: 26142167
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Factors Contributing to the Preference of Korean Patients with Crohn's Disease When Selecting an Anti-Tumor Necrosis Factor Agent (CHOICE Study).
    Kim ES; Kim KO; Jang BI; Lee CK; Kim HJ; Lee KM; Kim YS; Eun CS; Jung SA; Yang SK; Lee J; Kim TO; Jung Y; Seo GS; Yoon SM;
    Gut Liver; 2016 May; 10(3):391-8. PubMed ID: 26347512
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effectiveness of anti-TNFα drugs in patients with Crohn's disease who do not achieve remission with their first anti-TNFα agent.
    R-Grau Mdel C; Chaparro M; Mesonero F; Barreiro-de Acosta M; Castro L; Castro M; Domènech E; Mancenido N; Pérez-Calle JL; Taxonera C; Barrio J; De Francisco R; Fernández-Salgado E; Luzón L; Merino O; Oltra L; Saro C; Bermejo F; García-Sánchez V; Ginard D; Gutiérrez A; Vera I; Antón R; Ber Y; Calvet X; Gisbert JP
    Dig Liver Dis; 2016 Jun; 48(6):613-9. PubMed ID: 26992847
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Postoperative therapy with infliximab prevents long-term Crohn's disease recurrence.
    Regueiro M; Kip KE; Baidoo L; Swoger JM; Schraut W
    Clin Gastroenterol Hepatol; 2014 Sep; 12(9):1494-502.e1. PubMed ID: 24440221
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials.
    Cholapranee A; Hazlewood GS; Kaplan GG; Peyrin-Biroulet L; Ananthakrishnan AN
    Aliment Pharmacol Ther; 2017 May; 45(10):1291-1302. PubMed ID: 28326566
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease.
    Lindsay JO; Armuzzi A; Gisbert JP; Bokemeyer B; Peyrin-Biroulet L; Nguyen GC; Smyth M; Patel H
    Dig Liver Dis; 2017 Oct; 49(10):1086-1091. PubMed ID: 28826571
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Safety of anti-tumor necrosis factor therapy during pregnancy in patients with inflammatory bowel disease.
    Androulakis I; Zavos C; Christopoulos P; Mastorakos G; Gazouli M
    World J Gastroenterol; 2015 Dec; 21(47):13205-11. PubMed ID: 26715803
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparable outcomes of the consistent use versus switched use of anti- tumor necrosis factor agents in postoperative recurrent Crohn's disease following ileocolonic resection.
    Li Y; Stocchi L; Rui Y; Remzi FH; Shen B
    Int J Colorectal Dis; 2016 Nov; 31(11):1751-1758. PubMed ID: 27475090
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Review article: infliximab for Crohn's disease treatment--shifting therapeutic strategies after 10 years of clinical experience.
    Danese S; Colombel JF; Reinisch W; Rutgeerts PJ
    Aliment Pharmacol Ther; 2011 Apr; 33(8):857-69. PubMed ID: 21320139
    [TBL] [Abstract][Full Text] [Related]  

  • 56. SAFETY PROFILE OF ANTI-TNF THERAPY IN CROHN'S DISEASE MANAGEMENT: A BRAZILIAN SINGLE-CENTER DIRECT RETROSPECTIVE COMPARISON BETWEEN INFLIXIMAB AND ADALIMUMAB.
    Bau M; Zacharias P; Ribeiro DA; Boaron L; Steckert Filho A; Kotze PG
    Arq Gastroenterol; 2017 Dec; 54(4):328-332. PubMed ID: 28954043
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Concomitant therapy with methotrexate and anti-TNF-α in pediatric patients with refractory crohn's colitis: a case series.
    Absah I; Faubion WA
    Inflamm Bowel Dis; 2012 Aug; 18(8):1488-92. PubMed ID: 21882301
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Review article: why, when and how to de-escalate therapy in inflammatory bowel diseases.
    Pariente B; Laharie D
    Aliment Pharmacol Ther; 2014 Aug; 40(4):338-53. PubMed ID: 24957164
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Systematic review with meta-analysis: risk of post-operative complications associated with pre-operative exposure to anti-tumour necrosis factor agents for Crohn's disease.
    Lin YS; Cheng SW; Wang YH; Chen KH; Fang CJ; Chen C
    Aliment Pharmacol Ther; 2019 Apr; 49(8):966-977. PubMed ID: 30864199
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Preventive therapy in postoperative Crohn's disease.
    Swoger JM; Regueiro M
    Curr Opin Gastroenterol; 2010 Jul; 26(4):337-43. PubMed ID: 20571386
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.